Spots Global Cancer Trial Database for LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas

Official Title: Safety and Efficacy of LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas

Study ID: NCT05663125

Conditions

Recurrent Glioblastoma

Interventions

Laser interstitial thermal therapy

Temozolomide

Study Description

Brief Summary: This study aims to investigate the safety and efficacy of Laser Interstitial Thermal Therapy (LITT) combined with postoperative early use of temozolomide in treating recurrent glioblastomas.

Detailed Description: This is an open-label, non-randomized Phase II study, planning to recruit about ten patients. The primary objective of this study is to investigate the safety of MRI-guided LITT in combination with the early application of temozolomide. The secondary outcome is to explore the efficacy of MRI-guided LITT combined with the early use of temozolomide in treating recurrent glioblastomas.